Journal of Nutritional Therapeutics https://www.lifescienceglobal.com/pms/index.php/jnt <p><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">The Mission of Journal of Nutritional Therepeutics is to integrate knowledge and principles of nutrition and pharmacology. It provides an educational perspective concerning the synergy that exists in natural nutrition and medicinal nutrition. Our goal is to improve human health through dissemination of nutritional and pharmacological sciences. Nutritional Pharmacy provides open and equitable access to our international and multidisciplinary audience.</span></p> en-US <h4>Policy for Journals/Articles with Open Access</h4> <p>Authors who publish with this journal agree to the following terms:</p> <ul> <li>Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a <a href="http://creativecommons.org/licenses/by/3.0/" target="_new">Creative Commons Attribution License</a> that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.<br /><br /></li> <li>Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work</li> </ul> <h4>Policy for Journals / Manuscript with Paid Access</h4> <p>Authors who publish with this journal agree to the following terms:</p> <ul> <li>Publisher retain copyright .<br /><br /></li> <li>Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .</li> </ul> support@lifescienceglobal.com (Support Manager) support@lifescienceglobal.com (Technical Support Staff) Tue, 22 Jan 2019 00:00:00 +0000 OJS 3.2.1.3 http://blogs.law.harvard.edu/tech/rss 60 Platelets Mitochondrial Function Depends on Coenzyme Q10 Concentration in Human Young, Not in Elderly Subjects https://www.lifescienceglobal.com/pms/index.php/jnt/article/view/5814 <p class="04-abstract">Ageing is characterized by a progressive decline in the physiological functions of various organs. Mitochondrial alterations occurring in senescence. Antioxidants, including coenzyme Q<sub>10</sub> concentration, fall with ageing and contribute to enhanced oxidative stress age-related diseases. The impairment of platelet mitochondrial function occurs in a broad spectrum of diseases.</p><p class="04-abstract"> The aim of this study was to evaluate mitochondrial function in platelets in elderly and young human controls and correlate it with a concentration of coenzyme Q<sub>10</sub>. Platelets mitochondrial function was determined by the use of High-Resolution Respirometry method.</p><p class="04-abstract">We did not find significantly decreased platelet mitochondrial function in elderly subjects. Dependence of platelets mitochondrial respiratory chain function and ATP production at Complex I on a concentration of coenzyme Q<sub>10</sub> in platelets and whole blood in young not in elderly human volunteers was documented. This dependence was not found for Complex II in any group. Platelet mitochondrial coenzyme Q<sub>10</sub> concentration was insufficient for improving platelet mitochondrial function in elderly human subjects. Recommending supplementation with coenzyme Q<sub>10 </sub>in elderly and aged humans is waranted.</p><p class="04-abstract">High-Resolution Respirometry method offers a perspective to diagnose mitochondrial energy metabolism which might be useful for further studies in patients with mitochondrial disorders. Our results could contribute to the explanation of platelets mitochondrial function in elderly and aged human subjects.</p> Anna Gvozdjáková, Zuzana Sumbalová, Jarmila Kucharská, Anežka Chládeková, Zuzana Rausová, Olga Vancová, Mária Kubalová, Zuzana Kuzmiaková, Michal Nemec, Olga Ulicná, Viliam Mojto Copyright (c) 2021 Journal of Nutritional Therapeutics https://www.lifescienceglobal.com/pms/index.php/jnt/article/view/5814 Fri, 18 Jan 2019 00:00:00 +0000 Effect of Combination of L-Arginine and L-Carnitine on Serum AGEs Level, Kidney and Endothelial Function in Patients with Chronic Heart Failure https://www.lifescienceglobal.com/pms/index.php/jnt/article/view/5815 <p class="04-abstract">The aim of the study to evaluate the effect of combination of L-Arginine with L-Carnitine on GFR, serum AGEs level and endothelial function in chronic heart failure (HF) patients with preserved ejection fraction (HFpEF).</p><p class="04-abstract"><em>Materials and Methods</em>: 35 patients with mean age 60,1 [56,7; 77,3] years with an established diagnosis of HFpEF were enrolled. The <em>patients were</em> randomly and <em>blindly divided into</em> 2 <em>groups:</em> first (1st) group pts were treated with a combination of L-Carnitine and L-Arginine in addition to standard treatment; 2nd group pts – with L-Arginine in addition to conventional treatment. Standard laboratory blood tests, lipid profile, glucose, renal and liver function tests, serum advanced glycation end-product (AGEs) level, echocardiographic examination, flow-mediated dilatation (FMD%) were performed for all patients baseline and after 10 days of treatment. The glomerular filtration rate (GFR) was estimated using the CKD-EPI formula.</p><p class="04-abstract"><em>Results</em>: Median level of AGEs was 1.72 [1.34; 1.93] mg/ml. The level of AGEs was correlated with age (R = 0.71, p&lt;0.05), disease duration (R = 0.69, p&lt;0.05). After 10 days of treatment with a combination of L-Carnitine with L-Arginine mean AGEs was decreased by 13.1% in comparison with L-Arginine treatment group (p=0.0003). After the treatment in 1<sup>st</sup> group mean AGEs was significantly lower in comparison with the 2<sup>nd</sup> group (p=0.004). Baseline median level of GFR was 81.2 [72,1; 86,2] ml/min and correlated with disease duration (R = 0.71, p&lt;0.05), AGEs level (R = -0.73, p&lt;0.05). The inclusion combination of L-arginine aspartate with L-Carnitine contributed to the significant increase of GFR level (p=0.003). The median FMD% level was 6.2 [4.4; 7.9] % and correlated with age (R=-0.61, p &lt; 0.05), GFR (R=0.54, p &lt; 0.05). After the 10 days it had been established significant increasing of FMD% level on 47.9 % in 1<sup>st</sup> group (p=0.0005), and on 29.3 % in 2<sup>nd</sup> group (p=0.003). Endothelial function normalizing was achieved in 10 (66 %) pts of 1<sup>st</sup> group and in 9 (45%) pts of 2<sup>nd</sup> group (p=0.002).</p><em>Conclusion</em>: The combination of L-Carnitine, and L-Arginine improves kidney, endothelial function and contributes to decreasing of AGEs level in pts with HFpEF. Olexandr Kuryata, Oksana Sirenko, Abdunaser Zabida Copyright (c) https://www.lifescienceglobal.com/pms/index.php/jnt/article/view/5815 Fri, 18 Jan 2019 00:00:00 +0000 Beneficial Effects of Pomegranate Fruit Consumption in Cardiovascular Diseases Prevention https://www.lifescienceglobal.com/pms/index.php/jnt/article/view/5816 <p class="04-abstract">Oxidative stress, dyslipidemia, hypercoagulability, endothelial dysfunction and inflammation are key elements in the development of atherosclerosis. Oxidative stress has been implicated as well in most of the key steps in the pathophysiology of atherosclerosis and the consequential clinical manifestations of cardiovascular diseases. In addition to the formation of atherosclerosis, oxidative stress acute thrombotic events, including dyslipidemia, the oxidation of low-density lipoproteins (LDLs) and plaque rupture leading to atherothrombosis and myocardial infarction. In the last decades, multiple experimental studies and clinical trials have demonstrated that diet plays a central role in the prevention of atherosclerosis. Pomegranate (<em>Punica granatum </em>L.) is one of nature’s most concentrated sources of antioxidants. It contains some very potent antioxidants (<em>i.e.</em> tannins, anthocyanins and flavonoids), which provide a wide spectrum of action against free radicals and are considered to be potent anti-atherogenic products. These properties make pomegranate a healthy fruit with a high potential in preventing cardiovascular diseases. In this review, we give an overview on the newest insights in the role of pomegranate in therapy of vascular diseases.</p> L. Benchagra, A. Hajjaji, M. Ramchoun, A. Khalil, H. Berrougui Copyright (c) https://www.lifescienceglobal.com/pms/index.php/jnt/article/view/5816 Fri, 18 Jan 2019 00:00:00 +0000